IMPORTANT: Please note that brynmawrurology.com is an imposter website and NOT affiliated with MidLantic Urology. No one from our practice will contact you from or direct you to that website. If you interact with that site, no one from our practice will be aware.

Reviews Patient Portal Online Bill Pay

Search site

Dedicated to improving care

Clinical Research

Elevating Urology Through Clinical Research

Conducting clinical research keeps us at the forefront of urology treatment and gives our patients access to promising treatments and expert knowledge. This research enables us to offer our patients in Philadelphia and surrounding counties the latest advancements in treatments.

Each clinical research trial follows strict guidelines to protect participants. Ask your doctor if there’s a trial that is right for you. Or call our Clinical Research Department at 610-667-0458.

Sponsors and CROs: Learn more about partnering with MidLantic Urology for your next urology trial.

Clinical Trials at MidLantic Urology

Clinical research trials play an essential role in bringing new treatments to our patients. Those who participate in trials enjoy the reassurance and security they get from being closely monitored, and the satisfaction that they are playing an important role in advancing medicine.

These clinical trials are currently available at MidLantic Urology.

Myriad-Polaris

NCT03872388

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

JnJ: PASenger PCR 3003

NCT07225946

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (KLK2-PASenger)

Novartis Act First

NCT06855277

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC (AcTFirst)

Oric 944-01

NCT05413421

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Telix TLX591-203

NCT06520345

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Telix 301-biPASS

NCT07052214

PSMA PET Combined With MRI for the Detection of PCa (BiPASS)

Novartis JSB462

NCT06991556

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Pfizer-Mevpro 3

NCT07028853

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

JnJ-NovaStar

NCT06500936

Evaluation of an mHealth Intervention to Promote Participation in Breast Cancer Screening in Argentina

CRETO-EAP

NCT06443944

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Core-008

NCT06567743

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Immunity Bio- ResQ133A

NCT06800963

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

Tyra 302

NCT06995677

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

Astellas 7465-CL-0209

NCT07475806

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

comPas-PCR3001

NCT04898634

A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

ABLE 22

NCT06545955

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

ABLE 32

NCT06510374

A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)

MK-004

NCT06136650

A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA)

Dendreon Boost

NCT06134232

An Open-Label, Multicenter Study of Subjects With Metastatic Castrate-Resistant Prostate Cancer Treated With PROVENGE® and Boosted With A Single Infusion of Sipuleucel-T to Measure Immune Response

Janssen Moonrise-1

NCT06319820

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

For more information or to enroll in one of these trials, call MidLantic’s Clinical Research Department at 610-667-0458.

A Trusted Team

Clinical trials help scientists better understand disease and develop new medications, treatments, and devices. Our clinical research team is comprised of top physicians and specialists experienced in clinical research. We provide our patients with the opportunity to participate in clinical trials and gain access to the latest therapy and technology available to treat their urologic condition.

Led by Dr. Laurence Belkoff, D.O., F.A.C.O.S and Clinical Research Director Cheryl Zinar, RN, BSN, together oversee a dedicated research team of RNs, Research Assistants and Regulatory Specialists. Backed by a research committee of eight board certified physicians, we continually strive to advance urology health.